Evidence map›Paper›PMID 35033956›Full record

ArticleDrug and alcohol dependence2022

Risk factors for COVID-19 among persons with substance use disorder (PWSUD) with hospital visits - United States, April 2020-December 2020.

Amy R Board, Sunkyung Kim, Joohyun Park, Lyna Schieber, Gabrielle F Miller, Jamison Pike, Laura J Cremer, Alice Asher

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Amy R BoardCDC COVID-19 Response, United States; Epidemic Intelligence Service, Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop S106-8, Atlanta, GA 30341, United States; Division of Overdose Prevention, National Center for Injury Prevention and Control, 4770 Buford Highway, Mailstop S106-8, Atlanta, GA 30341, United States. Electronic address: ocg3@cdc.gov.
Sunkyung KimCDC COVID-19 Response, United States; Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, 1600 Clifton Rd., NE, Mailstop H24-10, Atlanta, GA 30333, United States. Electronic address: wox0@cdc.gov.
Joohyun ParkCDC COVID-19 Response, United States; Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, 4770 Buford Highway, Mailstop S107-3, Atlanta, GA 30341, United States. Electronic address: ppw6@cdc.gov.
Lyna SchieberCDC COVID-19 Response, United States; Division of Overdose Prevention, National Center for Injury Prevention and Control, 4770 Buford Highway, Mailstop S106-8, Atlanta, GA 30341, United States. Electronic address: chn6@cdc.gov.
Gabrielle F MillerCDC COVID-19 Response, United States; Division of Injury Prevention, National Center for Injury Prevention and Control, 4770 Buford Highway, Mailstop S106-8, Atlanta, GA 30341, United States. Electronic address: ygm3@cdc.gov.
Jamison PikeCDC COVID-19 Response, United States; Immunization Services Division, National Center for Immunization and Respiratory Diseases, 1600 Clifton Rd., NE, Mailstop H24-4, Atlanta, GA 30333, United States. Electronic address: kqv1@cdc.gov.
Laura J CremerCDC COVID-19 Response, United States; Division of Overdose Prevention, National Center for Injury Prevention and Control, 4770 Buford Highway, Mailstop S106-8, Atlanta, GA 30341, United States. Electronic address: qah6@cdc.gov.
Alice AsherCDC COVID-19 Response, United States; Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 12 Corp Sq Blvd, Mailstop US12-3, Atlanta, GA 30329, United States. Electronic address: luq1@cdc.gov.
National Center for Injury Prevention and Control · USNational Center for Chronic Disease Prevention and Health Promotion · USNational Center for Emerging and Zoonotic Infectious Diseases · USNational Center for HIV/AIDS Viral Hepatitis STD and TB Prevention · USNational Center for Immunization and Respiratory Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSociodemographic factors and chronic conditions associated with coronavirus disease 2019 (COVID-19) among persons with substance use disorder (PWSUD) are not well understood. We identified risk factors associated with COVID-19 among PWSUD with hospital visits.

methodsUsing the Premier Healthcare Database Special COVID-19 Release, we conducted a case-control study using ICD-10-CM codes to identify PWSUD aged 12 years and older with hospital visits for any reason during April-December 2020. Multivariable logistic regression was used to calculate adjusted odds ratios (aOR) and 95% confidence intervals (CI) to identify factors associated with COVID-19 diagnosis among PWSUD (age, sex, race/ethnicity, U.S. Census Region, urban/rural classification, insurance payor type, comorbidities, and substance use disorder [SUD] type), and then stratified by SUD type.

resultsFrom April-December 2020, 18,298 (1.3%) of 1,429,154 persons with SUD in the database had a COVID-19 diagnosis. Among PWSUD, opioid use disorder (OUD; aOR = 1.24, 95% CI = 1.18-1.32), alcohol use disorder (AUD; aOR = 1.16, 95% CI = 1.11-1.22), cocaine or other stimulant use disorder (COUD; aOR = 1.28, 95% CI = 1.22-1.34), and multiple SUDs (aOR = 1.20, 95% CI = 1.15-1.26) were associated with higher odds of COVID-19, as were comorbidities such as chronic lower respiratory disease (aOR = 1.32, 95% CI = 1.26-1.37), chronic hepatitis (aOR = 1.45, 95% CI = 1.34-1.57), and diabetes (aOR = 1.78, 95% CI = 1.71-1.86).

conclusionsAmong a sample of PWSUD, OUD, AUD, COUD, multiple SUDs, and associated comorbidities were associated with COVID-19 diagnosis. Integration of COVID-related care, care of other comorbidities, and SUD treatment may benefit PWSUD. Future studies are needed to better understand COVID-19 prevention in this population and to reduce disparities among subpopulations at increased risk.

Indexed as

COVID-19Opioid-Related DisordersSubstance-Related DisordersCase-Control StudiesChildCOVID-19 TestingHospitalsHumansRisk FactorsSARS-CoV-2United StatesAlcohol use disorderCocaineCOVID-19OpioidSubstance use disorder

Identifiers

PMID35033956
PMCPMC8747842
OpenAlexW4205446465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.